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Abstract: Iron is required for the survival of most organisms, including bacteria, plants, and humans.
Its homeostasis in mammals must be fine-tuned to avoid iron deficiency with a reduced oxygen
transport and diminished activity of Fe-dependent enzymes, and also iron excess that may catalyze
the formation of highly reactive hydroxyl radicals, oxidative stress, and programmed cell death. The
advance in understanding the main players and mechanisms involved in iron regulation significantly
improved since the discovery of genes responsible for hemochromatosis, the IRE/IRPs machinery,
and the hepcidin-ferroportin axis. This review provides an update on the molecular mechanisms
regulating cellular and systemic Fe homeostasis and their roles in pathophysiologic conditions that
involve alterations of iron metabolism, and provides novel therapeutic strategies to prevent the
deleterious effect of its deficiency/overload.
Keywords: iron; iron metabolism; iron toxicity
1. Introduction
Iron (Fe) is a trace metal essential to ensure the survival of almost all organisms. Its participation in
heme- and iron-sulfur cluster (ISC)-containing proteins allows the involvement of Fe in a variety of vital
functions, including oxygen transport, DNA synthesis, metabolic energy, and cellular respiration [1,2].
However, the ability of Fe to exchange single electrons with a number of substrates can lead to the
generation of reactive oxygen species (ROS), as a result of Fe participation in the Fenton chemistry [3].
This triggers oxidative stress, lipid peroxidation, and DNA damage, which can lead to genomic
instability and DNA repair defects [4,5] that ultimately compromise cell viability and promote
programmed cell death (PCD) [6]. Under physiologic conditions these deleterious effects are prevented
by fine-tuned regulatory mechanisms, which maintain systemic and cellular Fe homeostasis [7] through
the cooperation of functional compartments (erythroid and proliferating cells), uptake and recycling
systems (enterocytes and splenic macrophages), storage elements (hepatocytes), and mobilization
processes that allow Fe trafficking through polarized cells and their corresponding organs, presumably
assisted by the poly-r(C)-binding protein-1 (PCBP-1)-mediated transport [8,9]. The treatments of
pathological conditions associated with Fe overload strongly improved with the introduction of Fe
chelators and the advance of chemical, immunohistochemical, scanning transmission X-ray microscopy,
and magnetic resonance imaging (MRI), important tools to monitor these conditions. Synchrotron X-ray
fluorescence (SXRF) and/or absorption (XAS) are among the best available techniques to determine Fe
forms and tissues distribution [10]. In addition, MRI is a powerful tool to detect and assess the size
of insoluble Fe deposits (hemosiderin) [11], although its sensitivity is not sufficient to visualize other
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potentially toxic forms of Fe, such as labile Fe or excess of cytosolic or soluble ferritin [12]. Growing
efforts are being made to correlate the results obtained from spatial analyses with SXRF and XAS, and
the distribution of Fe observed by MRI. These techniques mainly used in the diagnosis of hepatic
disorders, neurodegenerative [10] and cardiovascular diseases [11], will probably be extended to other
organs after further investigations. The growing number of data showing a role of Fe in pathologic
conditions was a stimulus to this review (Figure 1).
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Figure 1. The importance of Iron in pathophysiologic conditions. Essential to ensure survival, 
disruption of iron homeostasis has been shown to be involved in a variety of pathophysiological 
conditions, which include anemia and iron-overload related disorders. In particular, the importance 
of tissue iron accumulation in inflammation and infection, cancer, genetic, cardiovascular and 
neurodegenerative diseases continuously increases. 
2. Iron Metabolism 
In healthy individuals, the amount of body Fe is maintained within a range of 4–5 g [13] by  
a strict control of its absorption, mobilization, storage, and recycling. Fe excretion is not actively 
controlled and skin desquamation is the major mechanism described so far, accounting for about  
1–2 mg per day [14]. Contrarily, well studied are the processes of Fe uptake and recycling that 
supply the daily need for hemoglobin (Hb) synthesis (25–30 mg). Degradation of senescent red 
blood cells (RBCs) by splenic macrophages accounts for 90% of total Fe recycling, the remaining 10% 
comes from the diet [13]. This process occurs in the duodenum where the duodenal cytochrome b 
ferrireductase (Dcytb) reduces it to Fe(II), which is then offered to the divalent metal transporter-1 
(DMT-1) for cellular uptake [15]. DMT-1 (SMF-3 in C. elegans) is located on the apical membrane of 
duodenal epithelial cells and is involved also in Fe reabsorption from glomeruli filtration, recycling 
from RBCs and transfered from endosomal to cytosolic compartments [16]. The important role of 
DMT-1 is revealed by the pathologic conditions caused by its mutations, including a severe form of 
microcytic hypochromic anemia extensively studied in humans and in the Belgrade rat [17]. 
Inside the cell, the Fe levels are controlled by an elegant machinery involving the Iron 
Regulatory Proteins (IRPs) and the Iron Responsive Elements (IREs). In low Fe conditions, the high 
affinity binding of IRPs to IREs inhibits mRNA translation when located in 5’UTR (e.g., Ferritins) 
and stabilizes the mRNA when in the 3’UTR (e.g., transferrin receptor 1, TfR1). In conditions of  
Fe excess, ferritins are derepressed and TfR1 is downregulated [18]. This Fe-mediated 
post-transcriptional regulation modulates the expression of a series of proteins responsible for 
internalization and storage or utilization of this metal. This ensures that when in excess, Fe is readily 
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disruption of iron homeostasis has been shown to be involved in a variety of pathophysiological
conditions, which include anemia and iron-overload related disorders. In particular, the importance
of tissue iron accumulation in inflammation and infection, cancer, genetic, cardiovascular and
neurodegenerative diseases continuously increases.
2. Iron Metabolism
In healthy individuals, the amount of body Fe is maintained within a range of 4–5 g [13] by
a strict control of its absorption, mobilization, storage, and recycling. Fe excretion is not actively
controlled and skin desquamation is the major mechanism described so far, accounting for about
1–2 mg per day [14]. Contrarily, well studied are the processes of Fe uptake and recycling that supply
the daily need for hemoglobin (Hb) synthesis (25–30 mg). Degradation of senescent red blood cells
(RBCs) by splenic macrophages accounts for 90% of total Fe recycling, the remaining 10% comes from
the diet [13]. This process occurs in the duodenum where the duodenal cytochrome b ferrireductase
(Dcytb) reduces it to Fe(II), which is then offered to the divalent metal transporter-1 (DMT-1) for cellular
uptake [15]. DMT-1 (SMF-3 in C. elegans) is located on the apical membrane of duodenal epithelial cells
and is involved also in Fe reabsorption from glomeruli filtration, recycling from RBCs and transfered
from endosomal to cytosolic compartments [16]. The important role of DMT-1 is revealed by the
pathologic conditions caused by its mutations, including a severe form of microcytic hypochromic
anemia extensively studied in humans and in the Belgrade rat [17].
Inside the cell, the Fe levels are controlled by an elegant machinery involving the Iron Regulatory
Proteins (IRPs) and the Iron Responsive Elements (IREs). In low Fe conditions, the high affinity
binding of IRPs to IREs inhibits mRNA translation when located in 5’UTR (e.g., Ferritins) and
stabilizes the mRNA when in the 3’UTR (e.g., transferrin receptor 1, TfR1). In conditions of Fe
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excess, ferritins are derepressed and TfR1 is downregulated [18]. This Fe-mediated post-transcriptional
regulation modulates the expression of a series of proteins responsible for internalization and storage
or utilization of this metal. This ensures that when in excess, Fe is readily stored within the multimeric
ferritin made of H- (FtH) and L-chains (FtL), from which is released to satisfy possible intracellular
demands [19]. This system, partially conserved in animals, in C. elegans involves a cytosolic aconitase
(ACO-1) activated in response to hypoxia, while ferritin expression is regulated via activation of the
insulin/insulin-like (IIS) growth factor signaling pathway and is favored by increased intracellular
stress [16].
Cellular Fe export is mediated by Ferroportin-1 (Fpn1), the only Fe exporter described so far [20].
Its function to release Fe into circulation is supported by the ferroxidase activity of multicopper proteins,
namely hephaestin or ceruloplasmin (CP), that favor the formation of Fe-transferrin (Tf) complexes [12].
These bind to cellular surface TfRs for endocytosis and the Tf-Fe3+ complex is subsequently reduced
by STEAP3 ferrireductase, a step necessary to deliver Fe to mitochondria for heme synthesis and ISC
formation [21,22].
It was more recently shown that systemic Fe homeostasis is ensured by a body sensor, hepcidin,
a peptide hormone produced by the liver in response to Fe and inflammation. It is controlled also by
erythroferrone (ERFE), an erythroid protein produced upon erythropoietic stimulation that suppresses
the synthesis of hepcidin [23]. Hepcidin acts as negative regulator of Fe uptake by binding the Fe
exporter Fpn1, promoting its internalization and subsequent degradation [24], consequently, increased
levels of ERFE enhance Fe availability and release the inhibitory effect of hepcidin on Fe absorption [25].
Indeed, upregulation of hepcidin prevents duodenal Fe uptake and entry into circulation, recycling
from RBC heme-Fe and release from Fe stores. The important role of hepcidin in Fe metabolism leads
to considering it one, if not the main, regulator of Fe homeostasis [26].
3. Heme-Iron Regulation
Most of the body Fe is contained within the protoporphyrin ring of heme, an insertion catalyzed
by the mitochondrial enzyme ferrochelatase. Heme acts as prosthetic group in a variety of proteins
essential for cellular proliferation, differentiation, and proper functioning, named hemoproteins, which
include globins, cytochromes, myeloperoxidases, catalase, and guanylyl cyclase among others [27].
Similarly to Fe, accumulation of non-hemoprotein bound heme (referred as free heme) is
cytotoxic, as sensitizes tissue parenchyma cells to undergo apoptosis in response to pro-inflammatory
agonists [28,29]. Disruption of heme homeostasis in porphyrias, anemia, hemolytic diseases,
hyperuricaemia, intracerebral hemorrhage and neurological disorders, atherogenesis, were
demonstrated by its deficiency/accumulation. In addition, the ability of heme to elicit cytokine
production, vascular permeability, and recruitment of immune cells to the inflamed tissue confirm its
participation in the first stages of inflammatory conditions [30].
The deleterious effect of free heme relies on the capacity of Fe to participate in the Fenton
chemistry. Thus, the maintenance of heme homeostasis is essential to prevent its cytotoxicity and,
as such, the existence of a systemic and intracellular regulation is fundamental [31]. Two main
circulating proteins are upregulated in response to stressful conditions and afford protection against
the pro-oxidant effect of heme. Haptoglobin (Hp) immediately captures the cell-free Hb released in
circulation from RBCs disruption, thus preventing its further oxidations, while hemopexin (Hx) is
a heme scavenger that inhibits the cellular entry of free heme, delivering it safely to macrophages
and hepatocytes for Fe recycling [32,33]. A number of membrane heme transporters were discovered
so far to play an important role in heme homeostasis. Two Feline Leukemia Virus subgroup C
cellular Receptor (FLVCR) isoforms control heme extracellular trafficking, FLVCR1a is essential for
skeletal formation and vascular integrity, and FLVCR1b avoids heme accumulation during fetal
erythropoiesis [34,35]. The ubiquitous location of ATP-Binding Cassette, subfamily G, member 2
(ABCG2) at the apical membrane of the cells also facilitates heme extracellular export and prevents the
deleterious effects of its accumulation [36,37]. Intracellular heme trafficking is mainly mediated by
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the heme-importer heme-responsive gene 1 (HRG-1) [38], fundamental to ensure the recycling of this
molecule by erythrophagocytic macrophages [39]. Roles of heme importers have also been proposed
for the heme carrier protein 1 (HCP1), ABCB6, and FLVCR2 [40].
4. Genetic Disorders—Hemochromatosis
The importance of Fe in pathophysiologic conditions continuously increases [6] and the first
type of inherited disorders in which the contribution of this metal was well-established is hereditary
hemochromatosis (HH), caused by mutations in genes maintaining Fe homeostasis. Different types
of HH have been discovered so far and the severity of the phenotypes observed varies with the
gene(s) involved [41]. The most common type of HH (type I) is adult onset and accounts for >80%
of all hemochromatosis patients, mostly Caucasian. It is caused by mutations in the hereditary
hemochromatosis (HFE) protein and the most prevalent substitution is cysteine 282 to tyrosine. This
leads to the inability of HFE to sense increased levels of Fe and interact with TfR1 [42], which causes
decreased hepcidin expression, Fe overload, and possible liver dysfunction. The rare type III HH
has a similar phenotype, but caused by mutations in TfR2 gene that abolish its capacity to sense Fe
levels and interact with HJV and HFE in the liver. This results in a decrease of hepcidin expression
and increase of Fe accumulation in the liver and heart. Type II (juvenile HH) is a more severe disorder
that affects younger individuals and causes a fast and heavy Fe overload in the liver and parenchyma.
If left untreated, it leads to Fe-mediated multi-organ dysfunction. It is associated with mutations
in hemojuvelin (HJV) or hepcidin (type II a and type II b, respectively) and with extremely low
levels of serum hepcidin. Type IV HH (ferroportin disease) differs from the other ones for having an
autosomal dominant transmission and for not affecting hepcidin expression. It is caused by mutations
in the SLC40A gene, which encodes the Fe exporter Fpn, namely the hepcidin target [43]. Known
also as ferroportin disease, this is characterized by hyperferritinaemia, normal Tf saturation, and
Fe-loaded macrophages [44]. Several mutations have been described, most cause a loss of function,
while in few cases they cause a gain of function that results in high serum Ft concentration, elevated Tf
saturation, and accumulation of Fe in parenchymal cells [15,41,44,45]. Among the various mutations,
a characterized one is the Cys326 to Ser substitution [46], which abolishes a ferroportin crucial binding
site to hepcidin [47]. The introduction of C326S in the endogenous ferroportin locus in a knockin mouse
confirmed the phenotypic pattern of hepatic damage, increased risk of cirrhosis, and hepatocellular
carcinoma [48] observed in human type IV HH, which is caused by an unrestrained Fe export from
macrophages and enterocytes, and a lethal exocrine pancreatic function [47,49].
5. Iron Deficiency and Anemia
When reviewing the importance of Fe in pathophysiologic conditions it is common to refer
mainly to Fe overload and its deleterious effects. However, we should remind that disruption of Fe
homeostasis also implies a decrease in its level and subsequent biological consequences. Fe deficiency
is the most common disease worldwide and affects mainly children, women, and the elderly [50].
Decreased Fe levels may be associated with mild or severe anemia, conditions that develops when
body Fe stores are depleted and the supply of Fe to organs becomes compromised [51,52]. Various
causes may contribute to this condition, including genetic defects in proteins responsible for DNA
repair, as in Fanconi anemia [4,5,53], and rare genetic mutations occurring in TMPRSS6 (alias
matriptase-2) that cause iron refractory iron deficiency anemia (IRIDA). TMPRSS6 is a negative
regulator of hepcidin expression [45] and its single nucleotide polymorphisms positively correlate
with low serum Fe and serum ferritin [54]. Anemic conditions are often caused when increased
Fe demand do not meet the adequate supply and occur mainly in children and pregnant women.
In addition, enhanced Fe loss affects mostly elderly and results from the use of drugs that cause
gastrointestinal bleeding [55]. A contributor to Fe deficiency in elderly comes also from the continuous
exposure to subclinical inflammation, which, as described below, modulates hepcidin expression,
impairs the maintenance of Fe homeostasis, and leads to the development of anemia of chronic
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diseases (ACD) [56]. Novel therapeutic approaches to correct the anemia due to hepcidin excess
are still under investigation. Among them, the ablation of ERFE in mice was shown not to improve
inherited anemias with high hepcidin and ineffective erythropoiesis [57], while heparin administration
effectively reduced hepcidin expression. In mice, the therapeutic use of heparins without anticoagulant
activity increased the levels of serum Fe, ameliorating significantly the clinical symptoms associated
with anemia of inflammation and IRIDA. These results strongly suggest that endogenous heparan
sulfate proteoglycans contribute to regulate hepcidin expression. Humanized hepcidin monoclonal
antibodies as well as structured L-oligoribonucleotide are currently tested in clinical trials for the
treatment of cytokines-induced hypoferremia, aimed to prevent ferroportin–hepcidin interaction and
to reduce hepcidin expression [58].
6. Iron and Cancer
Fe homeostasis is altered in most cancer patients, who are affected by anemia in more than 40% of
cases [59] and up to 90% when undergoing chemotherapy [60]. The low availability of systemic Fe
is partially promoted by the tumor itself that sequesters the metal to ensure its proper growth [61].
In fact, Fe availability is fundamental for cell proliferation and thus highly up-taken by neoplastic
cells [62]. Changes in Fe metabolism characterize all phases of tumor development, from proliferation
to metastasis [4,62]. Abnormal expression of TfR1 and FtH [63–65] are observed in a variety of
cancers, as well as increased levels of circulating hepcidin [64], and these proteins are potential
clinical predictors for the prognosis of lung, breast, prostate, liver, and pancreatic cancer [66–69]. The
importance of Fe in tumor development has been confirmed in solid and blood tumors, including
lymphoma, and multiple myeloma [70,71], where adverse prognosis correlates to Fe load in the affected
tissue. The Fe deregulation in tumor cells is associated with ROS production, which promotes DNA
modification, strand breaks and is potentially mutagenic [72–75]. Among the effects of the oxidative
stress generated by Fe accumulation, which are relevant to malignant transformation, there is the
activation of signaling transduction pathways that are essential for tumor growth [67]. These include
p53, Wnt, NF-κB, Hypoxia-inducible factor (HIF), DNA replication and repair, cyclins and cell cycle
regulation, AKT, and epidermal (EGF) and vascular endothelial growth factor (VEGF) [61,67]. Recent
studies also indicate the capacity of Fe-driven ROS to induce epigenetic changes that favor tumor
metastasis, as they trigger mutations in hot spots and the suppression and/or activation of tumor
suppression genes and/or proto-oncogenes, respectively [4,5,61,67,75]. The inflammation associated
with cancer also contributes to Fe deregulation and promotion of DNA damage. Tumor immunology
is one of the most investigated fields known to play a dominant role in tumor growth [76] and also
aimed to the development of therapeutic strategies eliciting anti-tumor responses [77,78]. Further
investigations may be required to assess whether the potential combination of Fe chelators and immune
therapy could prevent tumor growth and/or relapse.
7. The Iron-Inflammation Connection
Inflammation plays a critical role in controlling Fe metabolism, as the pro-inflammatory cytokines
released upon immune cell activation alter the levels of proteins regulating Fe homeostasis [79]. Taking
into account that Fe is essential for proliferation of both prokaryotes and eukaryotes, disruption
of its homeostasis may either favor the establishment of the infection or act as a host defense
mechanism to defeat pathogen invasion [80,81]. The ability of Fe to impair cytokine secretion renders
individuals with Fe overload more susceptible to systemic infections than those with Fe deficiency,
therefore excess Fe favors pathogen competition for Fe and increases the morbidity and mortality of
infectious diseases [82]. An interesting hypothesis that was recently proposed is that macrophages and
T-lymphocytes take up and accumulate non-transferrin bound Fe (NTBI), thus acting as circulating
Fe storage compartments to protect different organs from Fe-dependent cytotoxicity [12,83]. The
engagement of pattern recognition receptors (PPRs) and the release of pro-inflammatory cytokines
(IL-6, IL-22, Oncostatin-M or Activin B) from these immune cells stimulate hepcidin expression, which
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is considered one of major host defense strategies against infection, an effect triggered by restricting Fe
availability to pathogens [84,85]. Macrophage Fe retention is protective in most of the cases, but it may
also inhibit protective anti-microbial strategies, which become no longer effective to prevent pathogen
growth. This is the case for intracellular invading organisms, as Salmonella typhimurium, able to induce
hepcidin expression and cellular Fe to ensure its own growth [84]. Much studied is the role of hepcidin
in malaria, in which high levels are associated with diminished hepatic growth and differentiation of
Plasmodium parasite [86]. Fe deficiency was shown to correlate with decreased malaria susceptibility
in mice and humans, and consistently excess Fe positively correlates with increased lethality. This
notion is also supported by the observation that, in a randomized scale trail, most children succumbing
to the infection were the ones receiving Fe supplementation [51,85]. Mouse studies indicate that the
disruption of Fe homeostasis could also underlie the poor outcome observed in pregnancy malaria,
which results in abortions, stillbirths, underweight babies, and fetal and maternal mortality. The
characteristic microvasculature of the placenta, composed of high and low blood flow regions, seems
to favor the sequestration of infected RBCs, the lysis of which is a cause of heme/Fe-mediated
cytotoxicity to trophoblasts and the fetus. While this would contribute to explain the correlation
between Fe overload and the severity of placental malaria (PM), further investigations are required to
assess whether this is due to a dysfunctional intracellular and extracellular heme/Fe trafficking [87].
An evolutionary defense strategy against malaria infection is provided by the inheritance of one
copy of defective beta globin gene, which confers survival advantage against this disease. However,
individuals carrying the two copies of the mutations and suffering from sickle cell disease (SCD)
develop vaso-occlusion, endothelial cell dysfunction and chronic vasculopathy, all symptoms mediated
by heme/Fe driven cytotoxicity that cannot be prevented by the low level of Hp and Hx plasma proteins
observed in these conditions. Therapeutic approaches based on the re-establishment of Fe homeostasis,
achieved by overexpression of FtH, are currently under investigations in mice, in which increased
levels FtH were shown to prevent Hb-mediated microvascular stasis and ameliorate the symptoms
associated [88].
8. Role of Iron in Cardiotoxicity
The involvement of inflammation in cardiotoxicity was extensively demonstrated in cancer
patients, in which severe cardiomyopathy remains a major concern of chemotherapeutic drugs
administration. The involvement of Fe metabolism in the adverse effects induced by anthracycline and
doxorubicin (DOX) treatment, as cardiomyopathies and congestive heart failure, was confirmed by
the protective role of Fe chelators. Preventing disruption of Fe homeostasis and restoring the normal
expression of Fe transporters, Fe chelator therapy in anthracycline-induced cardiotoxicity suppresses
the deleterious effects of Fe overload, of which its involvement was also demonstrated by the increased
susceptibility to this treatment of HFE-deficient mice [89]. Whether the use of Fe chelators may also
be applied to prevent common cardiac failure remains to be established [11]. Nevertheless, the role
of Fe in cardiovascular diseases (CVD) was extensively demonstrated in epidemiological studies,
reporting the existence of a positive correlation between Fe accumulation and CVD [90]. This notion
was further supported by the lower incidence of ischemic heart disease in Fe deficient patients. The
association between disruption of Fe homeostasis and atherosclerosis-driven ischemic CVD was first
postulated by Sullivan in 1980s, who indicated that increased Fe levels may enhance the risk of CVD.
This may explain the enhanced susceptibility to CVD of post-menopausal women when compared to
pre-menopausal [91,92], for whom a reduced level of hepcidin was assumed to diminish more than
50% the risks of CVD when compared to men of the same age. In agreement with this observation,
a number of investigations confirmed the protective effect of blood donations against CVD, as this
reduces body Fe stores and improves vascular function [93]. The importance of Fe in cardiac function
has been demonstrated also in studies using mice that were genetically deleted for TfR-1 or FPN
in cardiomyocytes and shown to develop severe cardiomyopathy and heart failure [94,95]. While
this is due to a phenotype associated with a heart Fe deficiency or Fe overload, respectively, the
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restoration of Fe homeostasis via supplementation or chelation of this metal further confirms its
dominant role in the development of CVD. Although little is known about cardiac Fe utilization, the
ratio between soluble TfR and serum ferritin has been shown indicative of acute myocardial infarction.
In particular, the levels of serum ferritin were demonstrated to directly correlate with the incidence
and progression of atherosclerosis, which leads ultimately to the occurrence of CVD [93,96–100]. This
notion is further confirmed by the increased expression of FtH and FtL in atherosclerotic lesions. The
involvement of Fe in modulating the activity of enzymes fundamental in the regulation of cholesterol
and triglycerides as well as in the induction of low-density lipoprotein (LDL) oxidative modifications
leads to formation of Fe-rich macrophages, i.e., foam cells, responsible for atherosclerotic plaque
development, progression and subsequent vulnerability for rupture [90,93,101]. Degradation of the
cell-free hemoglobin subsequently to intraplaque hemorrhages results in the release into circulation
of its heme prosthetic groups promotes unfettered production of free radicals and oxidative stress,
strongly involved in the development of atherosclerotic lesions. The cytotoxicity induced by continuous
release of heme in circulation, as in thalassemic and SCD suffering individuals, is apparently the leading
cause of CVD, a belief also confirmed by the protective effect of the Hb/heme scavenger Hp and
the heme degrading enzyme heme oxygenase 1 (HO-1) in the development of these pathologies.
Interestingly, a strong correlation was found between Hp polymorphic genotype and the level of Fe
within atherosclerotic plaques, macrophage infiltration, and plaque instability, all symptoms associated
with enhanced CVD risks. Moreover, the anti-oxidant and vasodilator properties of HO-1 prevented
heme/Fe-mediated endothelial dysfunction and atherogenic plaque formation [93,101]. The higher
occurrence of cardiovascular death and non-ischemic cardiovascular abnormalities in hemochromatosis
patients as well as the role of hepcidin in Fe retention by macrophages and their consequent
transformation into foam cells is currently under investigation. Contrarily to the expectations,
hepatic hepcidin expression does not seem to correlate with atherosclerosis progression, as increased
accumulation of Fe in macrophages of atherosclerotic mice does not promote atherosclerotic lesions or
calcification. However, despite the debate about whether Fe loaded macrophages would aggravate
atherosclerosis-mediated CVD, the beneficial effect of the Fe chelator deferoxamine on the recovery
of ischemia/reperfusion-induced animals and the outcome of patients submitted to coronary artery
bypass surgery [90] reveals the crucial role of Fe in the pathogenesis of CVD.
9. Iron, Aging, and Neurodegeneration
The pathologies mentioned above imply systemic and local dysregulations of Fe homeostasis,
but it is still not clear whether this is also the case for neurodegenerative diseases, in which Fe
overload is postulated as one of the main contributors to neuronal death. Fe is required for normal
brain functions, e.g., neural respiration and metabolic activities, myelin synthesis, production of
neurotransmitters and synaptic plasticity [102]. The importance of brain Fe homeostasis is also
indicated by the retardation and impaired cognitive abilities caused by its deficiency during early
development as well as the axonal degeneration and neuronal death triggered by its overload [13]. Fe
physiologically accumulates in aging brains via a mechanism that remains to be fully elucidated and
that is accompanied by a reduced expression of anti-oxidant proteins and repair mechanisms, which
contribute to Fe-mediated oxidative stress [102,103]. During aging, the disruption of Fe homeostasis
affects all organs and contributes to the senescence process. Nutritional habits could contribute to
increase Fe content, and meta-analysis studies indicated a positive correlation between elevated Fe
consumption and increased incidence of age-related pathologies [71]. This notion is also supported
by mouse experiments demonstrating that animals fed with an enriched Fe-diet senesce faster than
those maintained under a restricted Fe diet. The high level of inflammation and circulating hepcidin,
observed under these conditions, is accompanied by disrupted Fe homeostasis, altered levels of
Fe, and organs senescence, as particularly evident in liver, spleen, and gut [103,104]. However, it
remains poorly understood how increased dietary Fe uptake affects the brain. Nevertheless, it is well
known that the levels of Fe increase disproportionally in neurodegenerative diseases, e.g., Parkinson’s,
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Alzheimer’s, Huntington’s, Prions, and neurodegeneration with brain Fe accumulation (NBIA), when
compared to brains of elderly individuals [6,103,105]. It is established the involvement of this metal
in Friedrich’s ataxia, a disease characterized by progressive degeneration of sensory neurons in the
dorsal root ganglia caused by a mutation in the frataxin gene. Frataxin plays an essential role in
delivering Fe to mitochondrial pathways involved in ISC biogenesis [5] and when its functionality
is reduced below a critical threshold, Fe accumulates in mitochondria [106]. Reduced mitochondrial
functioning and impaired electron transport chain results in Fe-mediated ROS, which was shown to
positively correlate with the severity of Friedrich’s ataxia. Mitochondrial defects are also associated
with the pathogenesis of Parkinson’s disease (PD) [107], in which a compromised Fe transport to this
organelle leads to its accumulation and contributes for the formation of alpha-synuclein aggregates,
a hallmark of PD. Disruption of Fe homeostasis is also observed in patients suffering from early onset
Alzheimer’s disease (AD), where brain and cerebrospinal fluid (CSF) accumulation [108] promotes
β-amyloid aggregation and hyperphosphorylated tau, two typical features of AD [105]. While different
expression or mutations in genes regulating Fe metabolism underlie a number of neurodegenerative
diseases, including restless syndrome, neuroferritinopathies, and aceruloplasminemia [109,110], the
requirement of Fe also in maintaining lipids homeostasis may suggest a potential role for this metal in
demyelinating conditions. However, the observation that most of the clinical symptoms associated with
these diseases occur in adulthood implies the existence of protecting mechanisms that retard/prevent
brain Fe toxicity. Whether the deleterious effect of brain Fe accumulation is associated with exposure
to sub-lethal chronic or acute inflammation is currently the object of investigations [102]. A high level
of pro-inflammatory cytokines has been detected in the affected brain regions and they may regulate
local Fe homeostasis [111]. In addition, systemic inflammation significantly increases the expression
of brain hepcidin, suggesting the existence of a hepcidin/ferroportin axis that actively regulate Fe
in the brain. Whether the FPN1/hepcidin axis may be involved in a potential redistribution of Fe
between the peripheral and central compartment remains to be elucidated [58,102]. Detoxification
of brain Fe overload is a task pursued by Fe chelators, most of which have poor access to the brain.
Promising results were obtained in clinical trials with deferiprone, a compound able to translocate
across the blood brain barrier and scavenge excess Fe from regional foci of siderosis. By efficiently
relocating this metal, deferiprone replenishes Fe-deprived regions and prevents the deleterious effects
of Fe maldistribution [12,112].
10. Conclusions
Major advances in the understanding of the mechanisms regulating intracellular and systemic
levels of Fe proved that the alteration of Fe homeostasis in mammals underlies a variety of pathological
conditions. The oxidative damage generated by the participation of Fe in redox reactions was shown
to be the leading cause of programmed cell death and tissue damage, which might also be enhanced
by the improper compartmentalization of this metal rather than its total accumulation. Now, the
challenge is in developing new approaches capable to restore the deregulation of Fe that accompanies
and exacerbates these disorders, which are capable of specifically targeting the tissues involved.
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